Abstract:Chang Qi 1 &ast, Sheng-Wen Sun 2 &ast, Xian-Zhi Xiong 1 1 Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xian-Zhi Xiong, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China, Tel/Fax +86 27-85726705, Email Many studies have proved that the pathogenesis of the chronic obstructive pulmonary disease (COPD) and lung cancer is related, and may cause and affect each other to a certain extent. In fact, the change of chronic airway obstruction will continue to have an impact on the screening, treatment, and prognosis of lung cancer.In this comprehensive review, we outlined the links and heterogeneity between COPD and lung cancer and finds that factors such as gene expression and genetic susceptibility, epigenetics, smoking, epithelial mesenchymal transformation (EMT), chronic inflammation, and oxidative stress injury may all play a role in the process. Although the relationship between these two diseases have been largely determined, the methods to prevent lung cancer in COPD patients are still limited. Early diagnosis is still the key to a better prognosis. Thus, it is necessary to establish more intuitive screening evaluation criteria and find suitable biomarkers for lung cancer screening in high-risk populations with COPD. Some studies have indicated that COPD may change the efficacy of anti-tumor therapy by affecting the response of lung cancer patients to immune checkpoint inhibitors (ICIs). And for lung cancer patients with COPD, the standardized management of COPD can improve the prognosis. The treatment of lung cancer patients with COPD is an individualized, comprehensive, and precise process. The development of new targets and new strategies of molecular targeted therapy may be the breakthrough for disease treatment in the future. Graphical Keywords: COPD, lung cancer, endo-phenotyping of COPD, early diagnosis, biomarkers, immunotherapy Graphical Lung cancer has the highest case fatality rate of any tumor, according to a large number of data statistics, 1 and chronic obstructive pulmonary disease (COPD) is a common comorbidity of non small cell lung cancer (NSCLC). 2 In the 1980s, Skillrud and Tockman et al first proposed that the increasing incidence and mortality of lung cancer were related to the presence of airway obstruction and impairment of lung function. 3 A comprehensive analysis by the International Lung Cancer Federation demonstrated that COPD was independently associated with SCLC after adjustment for age, sex, and years of smoking. 4 Multifactor proportional risk analysis showed that patients with mild ventilatory dysfunction were more likely to suffer lung cancer than moderate and severe ventilatory dysfunction. Patients with moderate and severe ventilatory dysfunction were more likely to suffer lung cancer than persons with normal lung function. In addition, acute exacerbation of COPD, global initiative for chronic obstructive lung disease (GOLD) stage, and emphysema were also independent predictors of lung cancer, 5 among which GOLD I/II, older age, low BMI, and DLCO < 80% were more closely associated. 6 Lung cancer, in turn, is a significant factor in the morbidity and mortality of COPD. Zhang et al found that 50–70% of lung cancer patients demonstrated impaired lung function, especially those with squamous cell carcinoma with a higher probability of concomitant COPD in 2017. 7 Among many COPD, the high incidence rate of lung cancer is the highest, indicating that there may be a common mechanism and risk. In fact, many reviews have shown the relationship between COPD and lung cancer. However, due to the disease heterogeneity of COPD and lung cancer, the interaction and mechanism between chronic obstructive pulmonary disease and lung cancer are still controversial. Different from other relevant reviews, we expanded the scope of our study when discussing the association between COPD and lung cancer. The impact of COPD on lung cancer screening, prognosis, and anti-tumor treatment was focused on. In the long run, COPD is related to poor prognosis of lung cancer patients, but the special inflammatory environment of COPD may make lung cancer patients r -Abstract Truncated-

A retrospective study of diagnosis and treatment of chronic obstructive pulmonary disease in patients with primary bronchogenic carcinoma of lung

A Retrospective Study of Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease in Patients with Lung Cancer

Status of Coexisting Chronic Obstructive Pulmonary Disease and Its Clinicopathological Features in Patients Undergoing Lung Cancer Surgery: a Cross-Sectional Study of 3,006 Cases.

P014 Diagnosis and Treatment Experience of 101 Patients with Advanced NSCLC Complicated with Chronic Obstructive Pulmonary Disease

Analysis of clinical features and risk factors of COPD patients with lung cancer

Prevalence of Undiagnosed and Undertreated Chronic Obstructive Pulmonary Disease in Lung Cancer Population

From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis

The Prevalence of Undiagnosed Copd and Approaches to Promote Early Copd Diagnosis in Lung Cancer Population

[Investigation of Lung Cancer Patients Complicated with Chronic Obstructive Pulmonary Disease in Thoracic Surgical Department].

Timing of chronic obstructive pulmonary disease diagnosis in lung cancer prognosis: a clinical and genomic-based study

Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective

Chronic obstructive pulmonary disease alters the genetic landscape and tumor immune microenvironment in lung cancer patients

[Exploration of the treatment model for patients with advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease based on real-world data].

Clinical and genomic characteristics of lung cancer concomitant chronic obstructive pulmonary disease (COPD).

Clinical Characteristics and Survival of Lung Cancer Patients Associated with Multiple Primary Malignancies

Analysis of optimal treatment and prognostic factors in patients with small-cell lung cancer comorbid COPD

Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity

Post-Operative Outcomes in Non-Small Cell Lung Cancer Patients with Mild to Moderate Stage Chronic Obstructive Pulmonary Disease

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease